EIKN
Eikon Therapeutics, Inc. - Common Stock$5.54Price Chart
Quant Score History
0 weakest · 5 strongestNot enough price history to chart the score yet.
Technical Indicators
RSI (14)
32.6
Dividends & Splits
Ex-Dividend
No dividend history.
Split
No splits on record.
Company Overview
Statement fields are the latest reported fiscal year (FY2025 FY), not a rolling TTM.
Market Cap
17.00M
P/E
—
Fwd P/E
-0.84
P/B
-0.03
P/S
—
EV/Rev
—
Div Yield
—
Div/Share
—
Revenue (FY)
—
Net Income (FY)
—
EPS (FY)
—
Profit Margin
—
ROE
—
ROA
—
52W High
—
52W Low
—
50D MA
8.82
200D MA
—
Shares Out
3.07M
Analyst Target
24.33
Factor Grades
HoldValue
Growth
Profit.
Momentum
EPS Rev.
Quant Score: 2.9 / 5
Model score computed from reported data. Not a recommendation.
Risk & Return
Ann. Return
-59.74%
Volatility
91.56%
Sharpe
-0.99
Beta
—
Alpha
—
Max Drawdown
65.93%
VaR (95%)
9.52%
Sortino
-1.33
Upcoming Earnings
News
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Opens in a new tab ↗Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Opens in a new tab ↗Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Opens in a new tab ↗Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Opens in a new tab ↗Eikon Therapeutics to Participate in Investor Conferences in September 2026
Opens in a new tab ↗Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Opens in a new tab ↗Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Opens in a new tab ↗Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Opens in a new tab ↗Analysed Articles
20 scoredMean
+0.05
Bullish
1
Neutral
19
Bearish
0
Polarity of crawled news items tagged to this symbol.